Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,inventory,accountsPayable,shortLongTermDebt,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,effectOfExchangeRate,totalCashFromOperatingActivities,depreciation,otherCashflowsFromInvestingActivities,dividendsPaid,changeToInventory,otherCashflowsFromFinancingActivities,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,priceHint,exchange,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,shortName,marketState,market,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,marketCap,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,esgPopulated,tradeable,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,Shares Short 4,Short Ratio 4,Short % of Float 4,Short % of Shares Outstanding 4,Shares Short (prior month ) 4,Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry
t0,DSRLF,687001000.0,54709400,12800000,,110273000,1641000,85371000,59284000,183205000,112774000,112774000,-1653000,-543000,,,,24477000,271205000,158431000,88000000,-2501000,,85796000,85371000,112903000.0,18155000.0,290127000.0,954678000.0,84821000.0,42845000.0,1246446000.0,55948000.0,15989000.0,1039459000.0,99463000.0,154774000.0,-158884000.0,124329000.0,339881000.0,160213000.0,33080000.0,-49338000.0,140497000.0,713917000.0,26000.0,126000.0,166687000.0,191234000.0,65485000.0,,42699000,11041000,-25923000,-7531000,28011000,-32414000,56329000,-26093000,-8321000,105262000,51129000,4400000,-52053000,-30196000,113688000,12648000,-42480000,553704000.0,en-US,US,EQUITY,False,Delayed Quote,USD,2,PNK,200.0,1630503122,0.0,200.0,200.0,200.0,1,0,DIASORIN SPA,REGULAR,us_market,0.0,200.0 - 200.0,200.0,finmb_679534,Other OTC,DiaSorin S.p.A.,EUR,21,36,199.9998,999999.06,2.0E-4 - 232.0,-32.0,-0.13793103,0.0002,232.0,1.0,36.86636,0.005,-0.005715362,185.3121,14.687897,0.07926032,5.425,17.446,201.14964,-1.149643,10685139968,11.463946,15,America/New_York,EDT,-14400000,False,False,0.05,,,232.0,0.0,201.15,185.31,21,36,54.71M,,16.6M,57.54%,20.78%,,,,,,1.21,0.71%,1.00,0.50%,,0.00%,,"May 23, 2021",,,"Dec 30, 2020","Dec 30, 2020",28.12%,37.41%,17.84%,27.51%,881.31M,16.09,49.70%,602.9M,375.02M,247.87M,5.43,74.10%,340.01M,6.21,34.66M,3.62,4.46,17.45,304.56M,188.13M,Value,13040,Healthcare,2024,8,5,"DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",Saluggia,39 01 614871,VC,6,1514678400,1619740800,7,Italy,http://www.diasoringroup.com,86400,8,Via Crescentino,Diagnostics & Research
t-1,DSRLF,544700000.0,54709400,12500000,,88800000,1641000,67800000,51600000,155700000,89900000,89900000,1700000,-1000000,,,,21000000,227900000,138000000,72200000,-1100000,,67800000,67800000,361000000.0,,59300000.0,905700000.0,,,965000000.0,905700000.0,218300000.0,,59300000.0,,,,256100000.0,,,,129600000.0,474400000.0,,,,,,,42699000,0,-15700000,-7531000,-9600000,-32414000,144800000,-26093000,-8321000,93900000,51129000,-15700000,-52053000,-30196000,-9600000,26100000,-42480000,,en-US,US,EQUITY,False,Delayed Quote,USD,2,PNK,200.0,1630503122,0.0,200.0,200.0,200.0,1,0,DIASORIN SPA,REGULAR,us_market,0.0,200.0 - 200.0,200.0,finmb_679534,Other OTC,DiaSorin S.p.A.,EUR,21,36,199.9998,999999.06,2.0E-4 - 232.0,-32.0,-0.13793103,0.0002,232.0,1.0,36.86636,0.005,-0.005715362,185.3121,14.687897,0.07926032,5.425,17.446,201.14964,-1.149643,10685139968,11.463946,15,America/New_York,EDT,-14400000,False,False,0.05,,,232.0,0.0,201.15,185.31,21,36,54.71M,,16.6M,57.54%,20.78%,,,,,,1.21,0.71%,1.00,0.50%,,0.00%,,"May 23, 2021",,,"Dec 30, 2020","Dec 30, 2020",28.12%,37.41%,17.84%,27.51%,881.31M,16.09,49.70%,602.9M,375.02M,247.87M,5.43,74.10%,340.01M,6.21,34.66M,3.62,4.46,17.45,304.56M,188.13M,Value,13040,Healthcare,2024,8,5,"DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",Saluggia,39 01 614871,VC,6,1514678400,1619740800,7,Italy,http://www.diasoringroup.com,86400,8,Via Crescentino,Diagnostics & Research
t-2,DSRLF,596644000.0,54709400,13107000,,73248000,1641000,57023000,52682000,143464000,78531000,78531000,-856000,-1235000,,,,16225000,207687000,129156000,64223000,-5283000,,57023000,57023000,126054000.0,18155000.0,246733000.0,887013000.0,80502000.0,54199000.0,1133746000.0,55948000.0,,883111000.0,71354000.0,164315000.0,-70201000.0,121139000.0,138718000.0,152448000.0,37386000.0,14546000.0,126366000.0,595846000.0,26000.0,78642000.0,183203000.0,195283000.0,61880000.0,8000.0,42699000,6467000,-15435000,-3146000,-90852000,-32055000,-42334000,-2908000,-1267000,49621000,26191000,16001000,-51991000,-29417000,-32807000,17595000,-19710000,443398000.0,en-US,US,EQUITY,False,Delayed Quote,USD,2,PNK,200.0,1630503122,0.0,200.0,200.0,200.0,1,0,DIASORIN SPA,REGULAR,us_market,0.0,200.0 - 200.0,200.0,finmb_679534,Other OTC,DiaSorin S.p.A.,EUR,21,36,199.9998,999999.06,2.0E-4 - 232.0,-32.0,-0.13793103,0.0002,232.0,1.0,36.86636,0.005,-0.005715362,185.3121,14.687897,0.07926032,5.425,17.446,201.14964,-1.149643,10685139968,11.463946,15,America/New_York,EDT,-14400000,False,False,0.05,,,232.0,0.0,201.15,185.31,21,36,54.71M,,16.6M,57.54%,20.78%,,,,,,1.21,0.71%,1.00,0.50%,,0.00%,,"May 23, 2021",,,"Dec 30, 2020","Dec 30, 2020",28.12%,37.41%,17.84%,27.51%,881.31M,16.09,49.70%,602.9M,375.02M,247.87M,5.43,74.10%,340.01M,6.21,34.66M,3.62,4.46,17.45,304.56M,188.13M,Value,13040,Healthcare,2024,8,5,"DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",Saluggia,39 01 614871,VC,6,1514678400,1619740800,7,Italy,http://www.diasoringroup.com,86400,8,Via Crescentino,Diagnostics & Research
t-3,DSRLF,517200000.0,54709400,12400000,,49000000,1641000,37700000,53200000,120600000,49400000,49400000,5600000,-400000,,,,11300000,174600000,125200000,54000000,-400000,,37700000,37700000,377400000.0,,71000000.0,894600000.0,,,965600000.0,894600000.0,211400000.0,,71000000.0,,,35500000.0,215500000.0,,,,125800000.0,426900000.0,,,,,,,42699000,0,-16000000,-3146000,-700000,-32055000,23500000,-2908000,-1267000,55800000,26191000,-16000000,-51991000,-29417000,-700000,18100000,-19710000,,en-US,US,EQUITY,False,Delayed Quote,USD,2,PNK,200.0,1630503122,0.0,200.0,200.0,200.0,1,0,DIASORIN SPA,REGULAR,us_market,0.0,200.0 - 200.0,200.0,finmb_679534,Other OTC,DiaSorin S.p.A.,EUR,21,36,199.9998,999999.06,2.0E-4 - 232.0,-32.0,-0.13793103,0.0002,232.0,1.0,36.86636,0.005,-0.005715362,185.3121,14.687897,0.07926032,5.425,17.446,201.14964,-1.149643,10685139968,11.463946,15,America/New_York,EDT,-14400000,False,False,0.05,,,232.0,0.0,201.15,185.31,21,36,54.71M,,16.6M,57.54%,20.78%,,,,,,1.21,0.71%,1.00,0.50%,,0.00%,,"May 23, 2021",,,"Dec 30, 2020","Dec 30, 2020",28.12%,37.41%,17.84%,27.51%,881.31M,16.09,49.70%,602.9M,375.02M,247.87M,5.43,74.10%,340.01M,6.21,34.66M,3.62,4.46,17.45,304.56M,188.13M,Value,13040,Healthcare,2024,8,5,"DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics tests for private and hospital microbiology laboratories worldwide. The company offers testing kits for infectious diseases, such as gastrointestinal infections, bone and mineral metabolism, endocrinology, hypertension, oncology, onco-hematology, and autoimmunity. It also provides various immunodiagnostic platforms, including LIAISON XL, LIAISON XS, LIAISON QuantiFERON TB Gold PLUS, LIAISON Elastase-1, and LIAISON MDX. The company sells its products directly, as well as through an international network of independent distributors. DiaSorin S.p.A. has collaboration with QIAGEN to develop an ultra-sensitive diagnostic test for Lyme disease. The company was founded in 1968 and is headquartered in Saluggia, Italy.",Saluggia,39 01 614871,VC,6,1514678400,1619740800,7,Italy,http://www.diasoringroup.com,86400,8,Via Crescentino,Diagnostics & Research
